These findings suggest that ERCC1 overexpression contributes to oxaliplatin resistance in CRC in vivo, and highlight why ZEB2‐expressing CRC tumours may demonstrate limited response to FOLFOX therapy. Here, ERCC1 is linked to neoplasm.